Literature DB >> 25406558

[Comparison of caffeine citrate and aminophylline for treating primary apnea in premature infants].

Jing-Lin Xu1, Rui-Quan Wang, Dong-Mei Chen.   

Abstract

OBJECTIVE: To investigate the clinical efficacy and safety of caffeine citrate and aminophylline in the treatment of primary apnea in premature infants.
METHODS: The clinical data of 125 premature infants with primary apnea from March 2013 to March 2014 were retrospectively analyzed. According to the therapeutic strategy, the patients were divided into caffeine citrate group (n=65) and aminophylline group (n=60). The overall response rates and adverse reaction rates in the two groups were compared.
RESULTS: The overall response rate in the caffeine citrate group was 86% (56 cases), which was significantly higher than that in the aminophylline group (72%, 43 cases) (P<0.05). The adverse reactions in the caffeine citrate group included tachycardia (1 case), restlessness (5 cases), feeding intolerance (7 cases), electrolyte disturbance (2 cases), and high blood glucose (5 cases), the incidence of which was significantly lower than that in the aminophylline group (P<0.05).
CONCLUSIONS: Caffeine citrate is more effective and causes fewer adverse reactions than aminophylline in the treatment of primary apnea in premature infants.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25406558

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  2 in total

1.  Specific Premature Groups Have Better Benefits When Treating Apnea With Caffeine Than Aminophylline/Theophylline.

Authors:  Yi-Chieh Lin; Yin-Ling Tan; Ting-An Yen; Chien-Yi Chen; Po-Nien Tsao; Hung-Chieh Chou
Journal:  Front Pediatr       Date:  2022-02-24       Impact factor: 3.418

2.  Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.

Authors:  Yiqun Miao; Yun Zhou; Shuliang Zhao; Wenwen Liu; Aihua Wang; Yuanyuan Zhang; Yanan Li; Huimin Jiang
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.